

Atezolizumab IMpower130

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMpower130

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: In combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC  
Experimental Arm: Atezolizumab + Carboplatin plus nab-paclitaxel  
Control Arm: Carboplatin plus nab-paclitaxel



